GP
EW icon

Geneva Partners’s Edwards Lifesciences EW Stock Holding History

Geneva Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-36,603
Closed -$2.85M – 57
2019
Q4 		$2.85M Sell
36,603
-5,265
-13% -$411K 1.96% 23
2019
Q3 		$3.07M Buy
41,868
+963
+2% +$67.6K 2.39% 19
2019
Q2 		$2.52M Sell
40,905
-5,445
-12% -$329K 2.03% 22
2019
Q1 		$2.99M Buy
+46,350
New +$2.65M 2.55% 15

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geneva Partners's EW Position: Q1 2020 in Review

Geneva Partners sold out of Edwards Lifesciences (EW) in Q1 2020, closing a stake of 36,603 shares — an estimated $2.85M sold.

Geneva Partners first reported a position in EW in Q1 2019 and held it in 4 quarters. The position peaked at $3.07M in Q3 2019. 1,019 funds tracked by Wall St. Rank hold EW as of Q1 2020.

  • Geneva Partners reported no remaining Edwards Lifesciences position as of Q1 2020 after selling out during the quarter.
  • Geneva Partners sold 36,603 Edwards Lifesciences shares in Q1 2020, an estimated $2.85M.
  • Geneva Partners first reported a position in Edwards Lifesciences in Q1 2019 and held it in 4 quarters.
  • Geneva Partners's Edwards Lifesciences position peaked at $3.07M in Q3 2019.
  • 1,019 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2020.

Based on Geneva Partners's 13F filing for Q1 2020, filed 27 Apr 2020.